Alan J Thompson

Q: What Schools Are Affiliated With Alan J Thompson

Alan J Thompson is affiliated with the following schools: University College London, Trinity College Dublin, University of Illinois Chicago

Alan J Thompson's AcademicInfluence.com Rankings

Alan J Thompson

Medical

#804

Historical Rank

Neurology

#90

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Alan J Thompson Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Alan J. Thompson, MD, FMedSci, FRCP, FRCPI, is Dean of the Faculty of Brain Sciences at UCL; Pro-Provost for London at UCL; Garfield Weston Professor of Clinical Neurology and Neurorehabilitation at the UCL Queen Square Institute of Neurology. He is also a consultant neurologist at the University College London NHS Hospitals Foundation Trust working at the National Hospital for Neurology and Neurosurgery. He is Editor-in-Chief for Multiple Sclerosis Journal.

(See a Problem?)

Alan J Thompson's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria (2011) (8941)
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (2001) (6788)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” (2005) (5003)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2017) (3544)
Defining the clinical course of multiple sclerosis (2014) (2372)
Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging (2003) (2168)
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. (1999) (1137)
The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. (2001) (923)
Neural correlates of motor recovery after stroke: a longitudinal fMRI study. (2003) (907)
Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity (2014) (902)
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. (2008) (839)
Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability (1999) (731)
Measuring the impact of MS on walking ability (2003) (643)
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis (1999) (637)
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. (2002) (632)
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. (1996) (628)
Neural correlates of outcome after stroke: a cross-sectional fMRI study. (2003) (611)
Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. (1990) (592)
Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study (2012) (562)
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis (2005) (555)
Functional-anatomical validation and individual variation of diffusion tractography-based segmentation of the human thalamus. (2005) (554)
Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis (2005) (512)
Multiple sclerosis (2018) (497)
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. (1998) (494)
Major differences in the dynamics of primary and secondary progressive multiple sclerosis (1991) (493)
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. (1996) (485)
A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. (2002) (484)
Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations (2007) (450)
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. (2002) (447)
New insights into the burden and costs of multiple sclerosis in Europe (2017) (416)
Diffusion-based tractography in neurological disorders: concepts, applications, and future developments (2008) (398)
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. (1991) (396)
Motor system activation after subcortical stroke depends on corticospinal system integrity. (2006) (389)
Diagnostic criteria for primary progressive multiple sclerosis: A position paper (2000) (383)
Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel Index and the Functional Independence Measure (1999) (378)
Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes. (2004) (375)
Gray matter atrophy is related to long‐term disability in multiple sclerosis (2008) (374)
Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. (1995) (370)
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke (2000) (368)
Correlation of magnetization transfer ration with clinical disability in multiple sclerosis (1994) (348)
MRI in multiple sclerosis: current status and future prospects (2008) (342)
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. (2003) (337)
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study (2007) (334)
The therapeutic potential of cannabis (2003) (326)
Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up (2005) (321)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis (2018) (319)
Executive function in multiple sclerosis. The role of frontal lobe pathology. (1997) (316)
Spinal cord MRI using multi‐array coils and fast spin echo (1993) (315)
The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. (2000) (313)
Correlations between changes in disability and T2‐weighted brain MRI activity in multiple sclerosis (1995) (299)
Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. (1990) (295)
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes (2010) (295)
Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis (2002) (294)
A comparison of the pathology of primary and secondary progressive multiple sclerosis. (1994) (293)
Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. (2002) (281)
Primary progressive multiple sclerosis. (1997) (267)
EDMUS, a European database for multiple sclerosis. (1992) (264)
Exercise in patients with multiple sclerosis (2017) (263)
Deep gray matter volume loss drives disability worsening in multiple sclerosis (2017) (257)
The evolution of prefrontal inputs to the cortico-pontine system: diffusion imaging evidence from Macaque monkeys and humans. (2006) (256)
MRI criteria for MS in patients with clinically isolated syndromes (2010) (256)
An electrophysiological study of the mechanism of fatigue in multiple sclerosis. (1997) (248)
Disability, atrophy and cortical reorganization following spinal cord injury (2011) (246)
1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis (1997) (243)
Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome. (2004) (234)
Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis (2003) (234)
Spinal cord atrophy and disability in MS (1998) (233)
The impact of inpatient rehabilitation on progressive multiple sclerosis (1997) (233)
Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. (1999) (232)
Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration (1992) (230)
MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord injury: a prospective longitudinal study (2013) (225)
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis (2018) (224)
Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function (2017) (221)
Heterogeneity of blood‐brain barrier changes in multiple sclerosis (1990) (219)
Progression of regional grey matter atrophy in multiple sclerosis (2017) (217)
Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. (2004) (214)
Functional anatomy of interhemispheric cortical connections in the human brain (2006) (211)
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes (2005) (209)
From diffusion tractography to quantitative white matter tract measures: a reproducibility study (2003) (205)
High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. (1992) (204)
The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. (2000) (203)
MRI dynamics of brain and spinal cord in progressive multiple sclerosis. (1996) (199)
Quality of Life Measurement After Stroke: Uses and Abuses of the SF-36 (2002) (197)
Treatment of cognitive impairment in multiple sclerosis: position paper (2013) (196)
Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study (2000) (194)
Probabilistic diffusion tractography: a potential tool to assess the rate of disease progression in amyotrophic lateral sclerosis. (2006) (194)
Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: Evidence that axonal loss is a substrate of MRI-detected atrophy (2006) (194)
Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis (1996) (191)
The current state-of-the-art of spinal cord imaging: Applications (2014) (185)
Evidence-based measurement (2001) (184)
Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in amyotrophic lateral sclerosis (2003) (183)
Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. (1995) (179)
Sensitivity of contrast enhanced MRI in multiple sclerosis. Effects of gadolinium dose, magnetization transfer contrast and delayed imaging. (1997) (178)
A study of the mechanisms of normal-appearing white matter damage in multiple sclerosis using diffusion tensor imaging (2003) (176)
Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: An in vivo study with TBSS and VBM (2009) (175)
Regional gray matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study. (2006) (173)
Characterizing function–structure relationships in the human visual system with functional MRI and diffusion tensor imaging (2004) (173)
Clinical outcomes assessment in multiple sclerosis (1996) (172)
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. (2007) (170)
Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. (1988) (167)
Brain MRI changes in phenylketonuria. Associations with dietary status. (1993) (165)
Gray and white matter volume changes in early RRMS (2005) (162)
Optic nerve diffusion tensor imaging in optic neuritis (2006) (162)
Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis (2002) (158)
Evaluating neurological outcome measures: the bare essentials. (1996) (158)
Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. (1996) (157)
Disability and T 2 MRI lesions: a 20 -year follow-up of patients with relapse onset of multiple sclerosis (2008) (154)
Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). (2006) (147)
Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples (2002) (146)
Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson’s disease with normal population health profiles (2003) (146)
What sample sizes for reliability and validity studies in neurology? (2012) (145)
The relationship between brain activity and peak grip force is modulated by corticospinal system integrity after subcortical stroke (2007) (143)
Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions (2010) (143)
Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management (2005) (143)
Progressive grey matter atrophy in clinically early relapsing-remitting multiple sclerosis (2003) (142)
Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study (2001) (140)
The reproducibility and sensitivity of brain tissue volume measurements derived from an SPM‐based segmentation methodology (2002) (140)
Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study. (2005) (139)
Spinal cord MRI using multi‐array coils and fast spin echo (1993) (137)
Investigation of white matter pathology in ALS and PLS using tract‐based spatial statistics (2009) (137)
Diffusion tractography based group mapping of major white-matter pathways in the human brain (2003) (137)
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. (1999) (136)
1H Magnetic resonance spectroscopy of normal appearing white matter in primary progressive multiple sclerosis (1999) (133)
Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis (2000) (132)
The SF-36 in multiple sclerosis: why basic assumptions must be tested (2001) (131)
Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS (1989) (131)
Multiple sclerosis: a preliminary study of selected variables affecting rehabilitation outcome (1999) (131)
Abnormalities of cerebral perfusion in multiple sclerosis (2004) (130)
Optic radiation changes after optic neuritis detected by tractography‐based group mapping (2005) (130)
How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales (2005) (129)
Neuroplasticity and functional recovery in multiple sclerosis (2012) (129)
The structural and functional mechanisms of motor recovery: complementary use of diffusion tensor and functional magnetic resonance imaging in a traumatic injury of the internal capsule (1998) (128)
The influence of time after stroke on brain activations during a motor task (2004) (128)
Primary progressive multiple sclerosis: a 5-year clinical and MR study. (2003) (126)
A serial MRI study following optic nerve mean area in acute optic neuritis. (2004) (126)
Neurological deterioration in young adults with phenylketonuria (1990) (124)
Self-efficacy predicts self-reported health status in multiple sclerosis (2004) (119)
The normal appearing grey matter in primary progressive multiple sclerosis (2003) (119)
Inpatient rehabilitation in multiple sclerosis (1999) (118)
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments (2011) (117)
The five item Barthel index (2001) (117)
Localization of grey matter atrophy in early RRMS (2006) (117)
Serial magnetization transfer imaging in acute optic neuritis. (2003) (116)
Multiple sclerosis lesion detection in the brain: A comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo (1997) (116)
Multisequence MRI in clinically isolated syndromes and the early development of MS (1999) (115)
Progressive cerebral atrophy in MS (2000) (113)
Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations (2000) (113)
Factors influencing work retention for people with multiple sclerosis (2005) (112)
Correlates of executive function in multiple sclerosis: the use of magnetic resonance spectroscopy as an index of focal pathology. (1999) (111)
Variations in T1 and T2 relaxation times of normal appearing white matter and lesions in multiple sclerosis (2000) (111)
A longitudinal study of cognition in primary progressive multiple sclerosis. (2005) (110)
Effects of a short outpatient rehabilitation treatment on disability of multiple sclerosis patients (2003) (110)
Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis. (2005) (108)
Predicting progression in primary progressive multiple sclerosis: A 10‐year multicenter study (2008) (107)
Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS (2012) (107)
Functional significance of the ipsilateral hemisphere during movement of the affected hand after stroke (2004) (107)
One year follow up study of primary and transitional progressive multiple sclerosis (2000) (107)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper (2016) (106)
Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis (2001) (106)
Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. (2005) (106)
Multiple sclerosis: assessment of disability and disability scales (1998) (105)
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting (2018) (104)
Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritis (2009) (102)
Selective magnetization transfer ratio decrease in the visual cortex following optic neuritis. (2006) (102)
T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. (2001) (101)
Community services in multiple sclerosis: still a matter of chance (2000) (101)
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs (1994) (99)
T1 lesion load and cerebral atrophy as a marker for clinical progression in patients with multiple sclerosis. A prospective 18 months follow‐up study (2001) (99)
Magnetic resonance imaging evidence of progression of subacute brain atrophy in moderate to severe traumatic brain injury. (2008) (98)
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis (2009) (97)
Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. (1997) (96)
A clinical and laboratory study of benign multiple sclerosis. (1986) (96)
Alpha gliadin antibody levels: a serological test for coeliac disease. (1983) (96)
Impact on Clinical and Cost Outcomes of a Centralized Approach to Acute Stroke Care in London: A Comparative Effectiveness Before and After Model (2013) (95)
Multiple sclerosis: diagnosis and the management of acute relapses (2005) (95)
Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR (2000) (93)
Spinal-cord MRI in multiple sclerosis (2003) (93)
Adaptive cortical plasticity in higher visual areas after acute optic neuritis (2005) (92)
Reduced gamma-aminobutyric acid concentration is associated with physical disability in progressive multiple sclerosis. (2015) (92)
Evidence-based measurement: Which disability scale for neurologic rehabilitation? (2001) (91)
Diffuse Lewy body disease. Neuropathological and biochemical studies of six patients. (1987) (90)
A Direct Demonstration of both Structure and Function in the Visual System: Combining Diffusion Tensor Imaging with Functional Magnetic Resonance Imaging (1999) (90)
The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study (2003) (89)
Diffusion tensor imaging in early relapsing-remitting multiple sclerosis (2001) (89)
Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis (2001) (88)
Seizures due to multiple sclerosis: seven patients with MRI correlations. (1993) (87)
Grey and white matter atrophy in early clinical stages of primary progressive multiple sclerosis (2004) (86)
Neuropsychological deficits in multiple sclerosis after acute relapse (1998) (86)
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? (2018) (86)
Capturing the true burden of dystonia on patients (2004) (86)
An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. (1998) (85)
Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis (1996) (84)
A (1)H magnetic resonance spectroscopy study of aging in parietal white matter: implications for trials in multiple sclerosis. (2000) (84)
Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales (2003) (84)
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi‐centre fMRI study (2008) (83)
MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction (2009) (83)
Longitudinal study of soluble adhesion molecules in multiple sclerosis (1997) (82)
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders (2019) (81)
Multiple sclerosis in the UK: service use, costs, quality of life and disability. (2008) (81)
Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI (2001) (80)
New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes (2003) (80)
Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities (2003) (80)
Increasing normal–appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing–remitting multiple sclerosis (2005) (79)
A questionnaire assessment of unmet needs for rehabilitation services and resources for people with multiple sclerosis: results of a pilot survey in five European countries (2000) (79)
Corticomotor representation to a human forearm muscle changes following cervical spinal cord injury (2011) (79)
Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes (2009) (79)
Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions (2014) (78)
A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. (1996) (78)
SYMPTOMATIC MANAGEMENT AND REHABILITATION IN MULTIPLE SCLEROSIS (2001) (78)
Tracking sensory system atrophy and outcome prediction in spinal cord injury (2015) (77)
Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study (2001) (77)
Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis (2004) (77)
Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study (2005) (76)
MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain (2007) (75)
A three-year, multi-parametric MRI study in patients at presentation with CIS (2008) (75)
Normal-appearing brain t1 relaxation time predicts disability in early primary progressive multiple sclerosis. (2007) (74)
Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis (2006) (74)
The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis (2002) (73)
Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials (1997) (72)
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (72)
Longitudinal Changes in Cerebral Response to Proprioceptive Input in Individual Patients after Stroke: An fMRI Study (2006) (72)
Does adding MS-specific items to a generic measure (the SF-36) improve measurement? (2001) (71)
Metabolite changes in early relapsing–remitting multiple sclerosis (2006) (71)
A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. (1993) (71)
A modified protocol to improve the detection of enhancing brain and spinal cord leasions in multiple sclerosis (2001) (71)
Imaging of the spinal cord and brain in multiple sclerosis: a comparative study between fast flair and fast spin echo (1997) (70)
Visual recovery following acute optic neuritis--a clinical, electrophysiological and magnetic resonance imaging study. (2004) (69)
A comprehensive assessment of cerebellar damage in multiple sclerosis using diffusion tractography and volumetric analysis (2011) (69)
Recovery after spinal cord relapse in multiple sclerosis is predicted by radial diffusivity (2010) (69)
Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. (1996) (69)
Fatigue is not associated with raised inflammatory markers in multiple sclerosis (2001) (68)
Progressive neurodegeneration following spinal cord injury (2018) (67)
Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis (2007) (67)
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study (2005) (66)
Quantitative 1H MRS imaging 14 years after presenting with a clinically isolated syndrome suggestive of multiple sclerosis (2002) (66)
Is inflammation important in early PPMS? a longitudinal MRI study (2005) (65)
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional C omposite (2004) (65)
Degeneration of the Injured Cervical Cord Is Associated with Remote Changes in Corticospinal Tract Integrity and Upper Limb Impairment (2012) (64)
The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. (2013) (63)
Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study (2009) (63)
MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob disease (2012) (63)
Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis (2003) (63)
Predicting outcome in clinically isolated syndrome using machine learning (2014) (63)
Recommendations for observational studies of comorbidity in multiple sclerosis (2016) (62)
Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. (1994) (62)
Does the extent of axonal loss and demyelination from chronic lesions in multiple sclerosis correlate with the clinical subgroup? (1999) (62)
Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest (2016) (61)
Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ? (1991) (61)
Early MRI in optic neuritis (2009) (60)
Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria. (1993) (60)
Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression (2018) (59)
Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis (2010) (59)
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition (2008) (58)
Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis (2010) (58)
Axonal integrity predicts cortical reorganisation following cervical injury (2012) (58)
The effectiveness of neurological rehabilitation in multiple sclerosis. (2000) (58)
Longitudinal evidence for anterograde trans-synaptic degeneration after optic neuritis. (2016) (57)
Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: Relationship to clinical parameters (1996) (57)
Symptomatic treatment and management of multiple sclerosis. (2014) (57)
MRI lesion volume measurement in multiple sclerosis and its correlation with disability: a comparison of fast fluid attenuated inversion recovery (fFLAIR) and spin echo sequences (1998) (56)
Diffuse Lewy body disease (2004) (56)
Interleukin 1 genotypes in multiple sclerosis and relationship to disease severity (2002) (56)
Effect sizes can be misleading: is it time to change the way we measure change? (2010) (56)
A 30‐Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes (2019) (56)
Reproducibility of fMRI in the clinical setting: Implications for trial designs (2008) (55)
Functional response to active and passive ankle movements with clinical correlations in patients with primary progressive multiple sclerosis (2006) (55)
Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta (2008) (55)
Cervical cord and brain grey matter atrophy independently associate with long-term MS disability (2010) (55)
Functional magnetic resonance imaging of the cortical response to photic stimulation in humans following optic neuritis recovery (2002) (55)
Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. (2008) (54)
T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis (2010) (54)
C onversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fl uid and neurophysiological findings (2003) (54)
Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. (2016) (53)
Tracking Changes following Spinal Cord Injury : Insights from Neuroimaging (2013) (53)
Diffusion tensor imaging of early relapsing-remitting multiple sclerosis with histogram analysis using automated segmentation and brain volume correction (2004) (53)
Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis (2008) (53)
Low Myo‐inositol indicating astrocytic damage in a case series of neuromyelitis optica (2013) (53)
Magnetisation transfer of normal appearing white matter in primary progressive multiple sclerosis (1999) (52)
Corpus callosum damage predicts disability progression and cognitive dysfunction in primary‐progressive MS after five years (2013) (52)
Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis (2004) (52)
Optic nerve magnetization transfer imaging and measures of axonal loss and demyelination in optic neuritis (2007) (51)
MRI features of benign multiple sclerosis (2009) (51)
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia (2006) (51)
Two-year follow-up study of primary and transitional progressive multiple sclerosis (2002) (51)
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis (2014) (50)
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. (2015) (50)
The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis (2000) (50)
Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis (1997) (50)
Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial (2006) (49)
Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups (1998) (49)
β‐Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: A regulatory role for cortisol and interleukin‐1 (1992) (49)
Estimation of the macromolecular proton fraction and bound pool T2 in multiple sclerosis. (2004) (49)
Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? (2003) (49)
Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis. (2001) (49)
Hippocampal atrophy in relapsing-remitting and primary progressive MS: a comparative study (2010) (49)
Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis (2009) (48)
Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis (2007) (47)
Central motor conduction time in progressive multiple sclerosis. Correlations with MRI and disease activity. (1998) (47)
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre (2003) (46)
Magnetization transfer ratio abnormalities reflect clinically relevant grey matter damage in multiple sclerosis (2009) (46)
Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. (1998) (46)
Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? (2002) (46)
Neutralising antibodies to interferon β during the treatment of multiple sclerosis (2003) (46)
Primary progressive multiple sclerosis diagnostic criteria: a reappraisal (2009) (45)
Reduced neurite density in the brain and cervical spinal cord in relapsing–remitting multiple sclerosis: A NODDI study (2020) (45)
Visual recovery following acute optic neuritis (2004) (45)
MRI only conversion to multiple sclerosis following a clinically isolated syndrome (2010) (45)
Progression on the Multiple Sclerosis Functional Composite in multiple sclerosis: what is the optimal cut-off for the three components? (2010) (45)
Talking the talk on walking the walk (2006) (44)
Upper cervical cord area in early relapsing‐remitting multiple sclerosis: Cross‐sectional study of factors influencing cord size (2006) (44)
Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study (1999) (44)
Neuroplasticity predicts outcome of optic neuritis independent of tissue damage (2010) (44)
Magnetic resonance imaging changes in early treated patients with phenylketonuria (1991) (44)
De-stabilizing and training effects of foot orthoses in multiple sclerosis (2006) (44)
Developing the ICF Core Sets for multiple sclerosis to specify functioning (2008) (43)
Voxel-based analysis of grey and white matter degeneration in cervical spondylotic myelopathy (2016) (43)
European validation of a standardized clinical description of multiple sclerosis (2004) (43)
Normal-appearing grey and white matter T1 abnormality in early relapsing–remitting multiple sclerosis: a longitudinal study (2007) (43)
Quantitative MRI of rostral spinal cord and brain regions is predictive of functional recovery in acute spinal cord injury (2018) (42)
Tracking Changes following Spinal Cord Injury (2013) (42)
Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis (2017) (42)
Frontiers in multiple sclerosis (1998) (42)
The challenge of comorbidity in clinical trials for multiple sclerosis (2016) (41)
DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime? (2015) (41)
Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. (1994) (41)
Dissecting structure–function interactions in acute optic neuritis to investigate neuroplasticity (2009) (40)
Brain lesion location and clinical status 20 years after a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis (2012) (40)
Evaluating neurorehabilitation: lessons from routine data collection (2005) (40)
Health-Related Quality of Life in People with Multiple Sclerosis Undergoing Inpatient Rehabilitation (1996) (40)
Neurorehabilitation in multiple sclerosis: foundations, facts and fiction (2005) (39)
Combining tractography and cortical measures to test system-specific hypotheses in multiple sclerosis (2010) (39)
Changes in Auditory Feedback Connections Determine the Severity of Speech Processing Deficits after Stroke (2012) (39)
Patient‐based outcomes of cervical dystonia: A review of rating scales (2004) (39)
Corticocortical coupling in chronic stroke (2004) (39)
The 2013 clinical course descriptors for multiple sclerosis (2020) (39)
Method for simultaneous voxel-based morphometry of the brain and cervical spinal cord area measurements using 3D-MDEFT (2010) (39)
Progressive MS: from pathophysiology to drug discovery (2015) (38)
Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis (1997) (38)
Monitoring disease activity and progression in primary progressive multiple sclerosis using MRI: sub-voxel registration to identify lesion changes and to detect cerebral atrophy (2002) (38)
Asymmetrical Activation of Human Visual Cortex Demonstrated by Functional MRI with Monocular Stimulation (2001) (38)
Spinal cord repair in MS (2010) (37)
Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR (2002) (37)
Magnetisation transfer ratio histogram analysis of primary progressive and other multiple sclerosis subgroups (2001) (37)
Factors Affecting Functional Outcome in Patients with Nontraumatic Spinal Cord Lesions After Inpatient Rehabilitation (2001) (37)
No association between the APOE ε4 allele and outcome and susceptibility in primary progressive multiple sclerosis (2000) (36)
Structural network disruption markers explain disability in multiple sclerosis (2018) (36)
T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis (2002) (36)
Behavioral and psychiatric symptoms in prion disease. (2014) (36)
Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and IQ. (1995) (36)
Multiple Sclerosis in the UK (2012) (36)
Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. (2004) (36)
PATHOGENESIS OF PROGRESSIVE MULTIPLE SCLEROSIS (1989) (36)
White and gray matter damage in primary progressive MS (2016) (35)
Embodied neurology: an integrative framework for neurological disorders (2016) (35)
The search for responsive clinical endpoints in primary progressive multiple sclerosis (2009) (35)
Water diffusion is elevated in widespread regions of normal-appearing white matter in multiple sclerosis and correlates with diffusion in focal lesions (2001) (35)
The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results (2001) (35)
Multiple Sclerosis: Clinical Challenges and Controversies (1997) (35)
An Automated Approach to Connectivity-Based Partitioning of Brain Structures (2005) (35)
Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis (2013) (35)
The transverse magnetisation decay characteristics of longstanding lesions and normal-appearing white matter in multiple sclerosis (1997) (35)
Exploring disability rating scale responsiveness II: Do more response options help? (2006) (34)
Multiple sclerosis: Symptomatic treatment (1996) (34)
Plasma cerebrosterol and magnetic resonance imaging measures in multiple sclerosis (2006) (34)
Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load (1997) (33)
Integrated care pathways in multiple sclerosis rehabilitation: completing the audit cycle (1998) (33)
Preliminary magnetic resonance study of the macromolecular proton fraction in white matter: a potential marker of myelin? (2003) (33)
Emergence of thalamic magnetization transfer ratio abnormality in early relapsing—remitting multiple sclerosis (2005) (33)
Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging (2008) (33)
Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. (2016) (33)
Dorsal and ventral horn atrophy is associated with clinical outcome after spinal cord injury (2018) (32)
Patterns of Brain Magnetic Resonance Abnormalities on T2-Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study (1998) (32)
Patterns of selective involvement of thigh muscles in neuromuscular disease (1988) (32)
Muscle paresis and passive stiffness: Key determinants in limiting function in Hereditary and Sporadic Spastic Paraparesis (2012) (32)
Ethics of placebo-controlled clinical trials in multiple sclerosis (2008) (31)
Quantification of optic nerve head topography in optic neuritis: a pilot study (2006) (31)
Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions? (2006) (31)
A retrospective analysis of outcome in severe Guillain-Barre syndrome following combined neurological and rehabilitation management (2000) (31)
Is the frequency of abnormalities on magnetic resonance imaging in isolated optic neuritis related to the prevalence of multiple sclerosis? A global comparison (2006) (30)
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis (2016) (30)
Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse? (1986) (29)
A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis (1996) (29)
Exploring rating scale responsiveness (2004) (29)
Grey matter damage and overall cognitive impairment in primary progressive multiple sclerosis (2011) (29)
Interferon beta-1a in primary progressive multiple sclerosis (2003) (28)
Biochemical changes within a multiple sclerosis plaque in vivo. (1991) (28)
TI-relaxation time changes over five years in relapsing-remitting multiple sclerosis (2010) (28)
Progressive neurodegeneration following spinal cord injury Implications for clinical trials (2018) (28)
Prospective study of neurorehabilitation in multiple sclerosis. (1997) (27)
The challenge of follow-on biologics for treatment of multiple sclerosis (2009) (27)
Serial MRI of the brain in asymptomatic patients infected with HIV: results from the UCMSM/Medical Research Council neurology cohort. (1994) (27)
The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis (2005) (27)
The Cervical Dystonia Impact Profile (CDIP-58): Can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria? (2008) (27)
Voxel-based cervical spinal cord mapping of diffusion abnormalities in MS-related myelitis (2014) (26)
Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study (2004) (26)
Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. (1995) (26)
Texture analysis of magnetization transfer maps from patients with clinically isolated syndrome and multiple sclerosis (2009) (26)
Evaluation of plasma tau and neurofilament light chain biomarkers in a 12-year clinical cohort of human prion diseases (2020) (25)
Control of spasticity in a multiple sclerosis model using central nervous system‐excluded CB1 cannabinoid receptor agonists (2014) (25)
Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life (2006) (25)
Complementary roles of grey matter MTR and T2 lesions in predicting progression in early PPMS (2010) (25)
Lesion enhancement diminishes with time in primary progressive multiple sclerosis (2010) (25)
PRION-1 scales analysis supports use of functional outcome measures in prion disease (2011) (24)
Patterns of disease activity in multiple sclerosis patients: A study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups (1996) (24)
Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort (2020) (24)
Landscape of MS patient cohorts and registries: Recommendations for maximizing impact (2017) (24)
New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom (2017) (23)
Review: Fluid biomarkers in the human prion diseases (2019) (23)
Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis (2019) (23)
Reproducibility of magnetic resonance imaging measurements of spinal cord atrophy: the role of quality assurance. (1999) (22)
A much-needed focus on progression in multiple sclerosis (2015) (22)
The cognitive profile of prion disease: a prospective clinical and imaging study (2015) (22)
MTR and T1 provide complementary information in MS NAWM, but not in lesions (2000) (22)
beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. (1992) (22)
Early pericalcarine atrophy in acute optic neuritis is associated with conversion to multiple sclerosis (2011) (22)
Symptomatic treatment in multiple sclerosis. (1998) (21)
Spasticity, ataxia and fatigue in multiple sclerosis. (1997) (21)
A Neurological Rehabilitation Unit: Audit of Activity and Outcome (1996) (21)
Expression of β2 adrenoreceptors on peripheral blood mononuclear cells in patients with primary and secondary progressive multiple sclerosis: a longitudinal six month study (2003) (21)
Suspected and clinically definite multiple sclerosis: the relationship between CSF immunoglobulins and clinical course. (1985) (20)
Interferon beta-1b treatment does not induce autoantibodies (2005) (20)
Pathologic correlates of the magnetization transfer ratio in multiple sclerosis (2020) (20)
Rehabilitation of the Cancer Patient: Experience in a Neurological Unit (2004) (20)
Multiple sclerosis—a global disorder and still poorly managed (2008) (20)
Adolescent and Adult Children of Parents with Parkinson's Disease: Incorporating Their Needs in Clinical Guidelines (2011) (20)
Quantitative EEG parameters correlate with the progression of human prion diseases (2016) (20)
Metabolic Changes in the Spinal Cord After Brachial Plexus Root Re-implantation (2013) (20)
Challenge of progressive multiple sclerosis therapy (2017) (19)
Predictive testing for inherited prion disease: report of 22 years experience (2014) (19)
HLA-DRB1*15 influences the development of brain tissue damage in early PPMS (2014) (19)
Evidence‐based guidelines for using the Short Form 36 in cervical dystonia (2007) (19)
Improved imaging of the spinal cord in multiple sclerosis using three-dimensional fast spin echo (1998) (19)
Structural cortical network reorganization associated with early conversion to multiple sclerosis (2018) (18)
Rehabilitation in a neuroscience centre: the role of expert assessment and selection (1996) (18)
Rehabilitation for patients with Parkinson's disease (2001) (18)
New treatments for multiple sclerosis: a clinical perspective (1996) (18)
Urinary neopterin and nitric oxide metabolites as markers of interferon β-1a activity in primary progressive multiple sclerosis (2010) (18)
Cannabinoids in MS: potentially useful but not just yet! (2002) (18)
T1 hypointensity of the spinal cord in multiple sclerosis (2001) (18)
Progress in neurorehabilitation in multiple sclerosis (2002) (18)
Central motor conduction in multiple sclerosis (1988) (17)
The influence of clinical relapses and steroid therapy on the development of Gd‐enhancing lesions: a longitudinal MRI study in relapsing—remitting multiple sclerosis patients (1997) (17)
Linking white matter tracts to associated cortical grey matter: A tract extension methodology (2012) (17)
Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study (2007) (17)
Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a (2003) (17)
Managing spasticity in people with multiple sclerosis: a goal-oriented approach to intrathecal baclofen therapy (2001) (16)
Applying the 2017 McDonald diagnostic criteria for multiple sclerosis – Authors' reply (2018) (16)
Primary Progressive Multiple Sclerosis (2005) (16)
Age Related Changes in Metabolite Concentrations in the Normal Spinal Cord (2014) (16)
Neurological rehabilitation: from mechanisms to management (2000) (16)
Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study (1994) (15)
Building an evidence base for multiple sclerosis management: support for physiotherapy (2001) (15)
Refinement and validation of the Parental Illness Impact Scale. (2010) (15)
Problems in designing and recruiting to therapeutic trials in primary progressive multiple sclerosis (1999) (15)
Multiple sclerosis and its pathophysiology (1992) (15)
Paradigm shifts: Early initiation of high-efficacy disease-modifying treatment in multiple sclerosis (2021) (15)
Cortical involvement determines impairment 30 years after a clinically isolated syndrome (2021) (15)
Treatment recommendations for interferon-β in multiple sclerosis (1999) (15)
[Diagnosis of multiple sclerosis]. (2003) (15)
Multiple sclerosis: rehabilitation measures. (1998) (14)
A blood miRNA signature associates with sporadic Creutzfeldt-Jakob disease diagnosis (2020) (14)
Asymmetric hemispheric representation of periictal heart rate modulation is individually lateralised (2011) (14)
The medical management of increased tone (1995) (14)
Rehabilitation of incomplete spinal cord pathology: Factors affecting prognosis and outcome (1996) (14)
WHO/MSIF: Atlas of MS: multiple sclerosis resources across the world (2008) (14)
White and grey matter atrophy in clinically early relapsing remitting multiple sclerosis. (2001) (13)
Early accurate diagnosis crucial in multiple sclerosis. (2015) (13)
Scanning Laser Polarimetry Quantification of Retinal Nerve Fiber Layer Thinning Following Optic Neuritis (2010) (13)
Three possible laboratory indexes of disease activity in multiple sclerosis (1987) (13)
Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies. (1985) (13)
*The Impact of In-patient Rehabilitation on Disability and Handicap in Progressive Multiple Sclerosis: A randomised controlled trial (1998) (13)
Longitudinal proxy measurements in multiple sclerosis: patient-proxy agreement on the impact of MS on daily life over a period of two years (2008) (13)
Unified understanding of MS course is required for drug development (2018) (13)
Spatial variability and changes of metabolite concentrations in the cortico‐spinal tract in multiple sclerosis using coronal CSI (2012) (13)
Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis (2016) (13)
A novel approach with “skeletonised MTR” measures tract‐specific microstructural changes in early primary‐progressive MS (2014) (13)
Integrated care pathways: disease-specific or process-specific? (2004) (12)
H-1 magnetic resonance spectroscopy of normal-appearing white matter in primary progressive multiple sclerosis (1998) (12)
Integrated care pathways: outcome from inpatient rehabilitation following nontraumatic spinal cord lesion (2002) (12)
Magnetic resonance imaging in primary progressive multiple sclerosis. (2002) (12)
The patient's experience of being a human subject (2008) (12)
Clinical relevance of cortical network dynamics in early primary progressive MS (2020) (12)
Cognitive problems in multiple sclerosis (1996) (12)
Atlas of MS 2020: Informing global policy change (2020) (12)
Socio-demographic variables are limited predictors of health status in multiple sclerosis (2003) (12)
Measuring handicap in multiple sclerosis (1999) (11)
Towards treating progressive multiple sclerosis (2020) (11)
Sudden Unexpected Death in Infancy: place and time of death (2006) (11)
The pathogenesis of lesions and normal appearing white matter changes in multiple sclerosis: A serial diffusion magnetic resonance imaging study (2000) (11)
The effect of interferon beta-1a on spasticity in primary progressive multiple sclerosis (2004) (10)
Integrated care pathways: evaluating inpatient rehabilitation in stroke (1997) (10)
The 2013 Clinical Course Descriptors for Multiple Sclerosis (2020) (10)
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a (2001) (10)
Is multiple sclerosis still a clinical diagnosis? (2003) (10)
Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis (2020) (10)
Assessment Measures and Clinical Scales (2001) (9)
The impact of inpatient neurorehabilitation on psychological well–being on discharge and at 3 month follow–up (2005) (9)
Multiple sclerosis progression: time for a new mechanism-driven framework (2022) (9)
CURRENT MANAGEMENT OF MULTIPLE SCLEROSIS (2000) (9)
Risk of neurosyphilis in HIV‐infected persons with syphilis lacking signs or symptoms of central nervous system infection (2018) (9)
The management of multiple sclerosis: current and future therapies. (1998) (9)
A longitudinal functional MRI study of non-arteritic anterior ischaemic optic neuropathy patients (2011) (9)
Disability and T2 MRI lesions: a 20 year follow-up of patients with relapse onset of MS (2008) (9)
Diagnosis of MS: a comparison of three different clinical settings (2003) (8)
Double-blind, placebo-controlled, MR monitored exploratory trial of chimeric anti-CD4 antibodies in MS. (1995) (8)
Patient dissatisfaction: Insights into the rehabilitation process (2004) (8)
MSIF Atlas of MS database update: multiple sclerosis resources in the world 2013 (2012) (8)
Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data (2001) (8)
Nuclear magnetic resonance monitoring of treatment and prediction of outcome in multiple sclerosis. (1999) (8)
The size of the treatment effect: do patients and proxies agree? (2009) (7)
Lesion heterogeneity in MS: a study of the relationships between appearances on T1-weighted images, T1 relaxation times and metabilite concentrations (2000) (7)
When are we going to take modifiable risk factors more seriously in multiple sclerosis? (2017) (7)
Relation of impairment to everyday competence in visual disorientation syndrome: evidence from a single case study. (2000) (7)
Patterns of disease activity in multiple sclerosis. (1990) (7)
Developing clinical outcome measures in multiple sclerosis: an evolving process (2002) (7)
Resolution of left hemisphere cognitive dysfunction in multiple sclerosis with magnetic resonance correlates: a case report. (1996) (7)
Inequality in the Availability of Expensive Treatments (1999) (7)
Assessing the quality of life of patients with multiple sclerosis (1997) (7)
Improving the quality of life of patients with multiple sclerosis: diagnosis. (1998) (7)
Benign multiple sclerosis (1999) (7)
Spinal cord atrophy and disability in multiple sclerosis: a longitudinal study (1998) (7)
Service delivery in multiple sclerosis: the need for co-ordinated community care (1996) (7)
A new test of memory for multiple sclerosis 1: Format development and stimuli design (2001) (7)
Rehabilitation of progressive neurological disorders: a worthwhile challenge. (1996) (7)
Improving function: a new treatment era for multiple sclerosis? (2009) (7)
Comparing caregiver anxiety across chronic and acute neurological conditions (2006) (6)
Diagnosis and management of primary progressive multiple sclerosis. (2008) (6)
Investigating the relationship between brain structure and function : combining diffusion tensor imaging with functional MRI in the visual system (1998) (6)
Neurite Orientation Dispersion and Density Imaging (NODDI) in RRMS (P4.159) (2015) (6)
Primary progressive multiple sclerosis presenting under the age of 18 years: Fact or fiction? (2020) (6)
Identification of brain atrophy with MRI in MS (1998) (6)
Reflections on 2008 (2009) (6)
Brainstem phenotype of cathepsin A–related arteriopathy with strokes and leukoencephalopathy (2017) (6)
Painful Extremities and Neurological Disorder in Essential Thrombocythaemia (1984) (6)
Atopic myelitis in a European woman residing in Japan (2010) (6)
Management of spasticity in hereditary spastic paraplegia. (1999) (6)
[Neurorehabilitation in multiple sclerosis]. (2005) (6)
Autopsy validation of MRI in central pontine myelinolysis (2004) (6)
The measure tells the tale: Clinical outcome measures in multiple sclerosis (2017) (6)
Quality of life and psychosocial well-being in people with multiple sclerosis and Parkinson’s disease (2007) (5)
ECTRIMS-EAN clinical practice guideline on pharmacological management of multiple sclerosis. (2016) (5)
Response of the multiple sclerosis community to COVID-19 (2020) (5)
Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial (2006) (5)
Measurement of neurological outcomes (2002) (5)
MULTIPLE sclerosis. (1948) (5)
Treatment of progressive multiple sclerosis (2003) (5)
Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale (2005) (5)
Quantification of T1 and T2 relaxation times in the normal appearing white matter and lesions of multiple sclerosis (2000) (5)
Overview of London trial of intramuscular interferon-b1a in primary-progressive multiple sclerosis (2004) (5)
Multiple Sclerosis International Federation: Stimulating international cooperation in research (2013) (5)
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination (1999) (5)
Principles of neurological rehabilitation (2000) (5)
0512 Getting the measure of spasticity in MS: The multiple sclerosis spasticity scale (MSSS-88) (2005) (5)
Soluble E-selectin in multiple sclerosis: Clinical and MRI correlation (1994) (5)
A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS) (2011) (4)
Serial Gd-DTPA MRI reveals differences between primary and secondary progressive multiple sclerosis (1989) (4)
A Predictive Model for Corticosteroid Response in Individual Patients with MS Relapses (2015) (4)
Shortening inpatient stay for stroke (2002) (4)
Spasticity rehabilitation: a rational approach to clinical management (1998) (4)
Development of novel clinical examination scales for the measurement of disease severity in Creutzfeldt-Jakob disease (2020) (4)
Intrathecal therapies, including baclofen and phenol (2006) (4)
Cerebral revascularisation : where are we now ? (2005) (4)
Neurological rehabilitation of multiple sclerosis (2006) (4)
Optic neuritis as a sentinel lesion to study neuroprotection and repair in a trial of autologous mesenchymal stem cells in multiple sclerosis (2008) (4)
Is inpatient rehabilitation effective in multiple sclerosis (1997) (4)
Use of magnetic-resonance spectroscopy to investigate disability in multiple-sclerosis (1994) (4)
Workshop on primary progressive multiple sclerosis: meeting summary (2002) (4)
Evaluating the role of botulinum toxin type A in adults with focal spasticity (1999) (4)
Possible in vivo modulation of Leu 2a expression on suppressor T cells in active multiple sclerosis. (1985) (4)
Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (2010) (4)
Connecting to the future – the promise of telecare (2012) (4)
Disrupted principal network organisation in multiple sclerosis relates to disability (2020) (4)
Myopathy in hypokalaemic periodic paralysis: reversal with acetazolamide. (1984) (3)
LETTERS TO THE EDITOR (1990) (3)
12-Item Multiple Sclerosis Walking Scale (2015) (3)
Patterns of disease activity in MS: an MRI study of brain and spinal cord (1989) (3)
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal (2021) (3)
HLA-DRB1*15 influences the development of brain tissue damage in early primary progressive multiple sclerosis (2013) (3)
Two years of COVID-19 in the MS community: What have we learnt so far? (2022) (3)
Acute central cervical cord injury due to disco dancing. (1983) (3)
Mark VII Microclimate System (cooling suit) in the symptomatic treatment of multiple sclerosis patients with marked temperature sensitivity (1996) (3)
POI18 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis (2010) (3)
Validation of the McDonald criteria in patients with clinically isolated syndromes (2002) (3)
Mechanisms of disability (1999) (3)
Neurite orientation dispersion and density imaging (NODDI) reflects early microstructural brain tissue changes in clinically isolated syndrome (CIS) (2016) (3)
Spatial patterns of brain lesions assessed through covariance estimations of lesional voxels in multiple Sclerosis: The SPACE-MS technique (2021) (3)
Triple dose gadolinium enhanced MRI of the brain and spinal cord in early relapsing remitting multiple sclerosis is predictive of future relapses (2002) (3)
Dissecting the familial risk of multiple sclerosis (2011) (3)
Towards a European Network for Multiple Sclerosis Trials (ENMST) (2003) (3)
Developing a measure of patients' experiences of relapse management in multiple sclerosis. (2003) (3)
Long term management of multiple sclerosis (1994) (3)
Rehabilitation of cognitive impairment (2008) (3)
Regional grey matter atrophy in early primary progressive multiple sclerosis: a voxel-based morphometry study (2005) (3)
Advancing trial design in progressive multiple sclerosis (2017) (3)
Rehabilitation in multiple sclerosis (1998) (3)
Genome-wide association study of behavioural and psychiatric features in human prion disease (2015) (3)
Redefining multiple sclerosis phenotypes using MRI (2019) (3)
A quadrant-specific monocular visual functional MRI paradigm designed to minimize attention and loss-of-fixation biases (2008) (2)
MRI and assessment of treatment in multiple sclerosis. (2001) (2)
Author Correction: Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data (2021) (2)
Using structural and functional magnetic resonance imaging to explain visual loss at the onset of acute optic neuritis (2008) (2)
Diagnosing and managing multiple sclerosis. (2009) (2)
Spinal cord 1H-MR spectroscopy in patients after brachial plexus root re-implantation. (2011) (2)
4-31-17 MRI protocol for the European trial of beta interferon-1b in secondary progressive multiple sclerosis (1997) (2)
Chronic cerebrospinal venous insufficiency (2010) (2)
Role of a baseline scan in predicting clinical and MRI activity of relapsing-remitting MS patients (1995) (2)
Multiple sclerosis: The disease and its treatment (2000) (2)
The Pacinian Corpuscle and John Shekleton (1985) (2)
Extensive brain activation following recovery from optic neuritis : a pilot study using functional magnetic resonance imaging (fMRI) (1999) (2)
Author response: Progressive neurodegeneration following spinal cord injury: Implications for clinical trials (2018) (2)
New criteria for the diagnosis of multiple sclerosis (2005) (2)
Preliminary validation of the self-report Barthel Index in people with Parkinson’s disease (2008) (2)
Application of mechanistic methods to clinical trials in multiple sclerosis: the simvastatin case (2018) (2)
Neurological association Proceedings of the 18th annual meeting of the Irish Neurological Association held in Galway on 5th and 6th November, 1982 (1983) (2)
Irish Neurological Association Proceedings of the 23rd Annual Scientific Meeting of the Irish Neurological Association — Galway, 9th–10th October 1987 (1988) (2)
Interferon beta-16 delays progression of disability in secondary progressive multiple sclerosis — results of the european multicenter study (1998) (2)
Evaluating the outcome of rehabilitation interventions (2004) (2)
Database for serial magnetic resonance imaging in multiple sclerosis (2004) (2)
Cannabinoids in multiple sclerosis (CAMS) study, follow-up data suggesting an effect on disease progression (2004) (2)
Removal of access to alemtuzumab for patients with aggressive multiple sclerosis (2013) (2)
Dumas, Zola, and the “locked‐in” syndrome (1985) (2)
MRI monitoring of cerebral atrophy during a placebo-controlled trial of interferon-beta-1b in secondary progressive multiple sclerosis (2000) (2)
Multiple sclerosis: the upward trajectory continues (2017) (2)
Immediate and long term effects of inpatient rehabilitation in progressive multiple sclerosis (MS): Initial report (1995) (2)
Assessing the Impact of Parental Illness on Adolescent and Adult Children (2005) (2)
Pathogenesis and mechanisms of disability (1997) (2)
Predicting clinical conversion to multiple sclerosis in patients with clinically isolated syndrome using machine learning techniques (2012) (2)
Neurological Complications of HIV Infection and AIDS (1996) (2)
Idiopathic Intracranial Hypertension and Multiple Sclerosis. (2021) (2)
Evidence for early neuronal damage in the cervical cord of patients with primary progressive multiple sclerosis (2013) (2)
Treatment for patients with primary progressive multiple sclerosis (2019) (2)
Multiple Sclerosis Spasticity Scale (2017) (2)
Metabolite changes in the white matter 3 years after a clinically isolated syndrome suggestive of multiple sclerosis (2006) (2)
Age and gender effects on brain grey and white matter volumes in normal controls: the reproducibility and sensitivity of an SPM based segmentation methodology. (2001) (2)
Chapter 1 The Diagnosis of Multiple Sclerosis (2003) (2)
Onset and duration of blood-brain barrier breakdown in multiple sclerosis (1991) (2)
Defining multiple sclerosis subtypes using machine learning (2019) (2)
Interferon-beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis (2000) (2)
An interdisciplinary team approach to acute stroke rehabilitation (2004) (1)
Anxiety, rather than depression, is the key to pain in MS (2004) (1)
Focal treatments, including botulinum toxin (2006) (1)
Cervical spinal cord volume estimation using an active surface method: a amgnetic resonance imaging study in multiple sclerosis (2001) (1)
A serial MRI study of spinal cord atrophy in multiple sclerosis using an active surface segmentation technique. (2002) (1)
White and grey matter damage in early primary-progressive multiple sclerosis: the chicken or the egg? (2013) (1)
Cognition, fatigue and health-related quality of life in patients with multiple sclerosis: results from a european-wide study (2016) (1)
Fexofenadine ‐ why is it still not available OTC in the UK? (2019) (1)
Commentary on the ECTRIMS–EAN guideline for pharmacological treatment of multiple sclerosis (2018) (1)
Longitudinal VBM of regional progression in human prion disease (2012) (1)
Optic nerves show gadolinium enhancement in early acute optic neuritis (1991) (1)
The potential for recovery and repair following stroke (2004) (1)
Grey and white matter atrophy in clinically early PPMS: one year follow-up study (2004) (1)
Cervical cord and brain grey matter atrophy, and T2 lesion load accrual, independently reflect the long-term disability in multiple sclerosis (2009) (1)
GPs have pivotal role in managing MS. (2007) (1)
Chapter 20 Rehabilitation in Multiple Sclerosis (2003) (1)
The predictive value of brain lesion load in determining brain atrophy in multiple sclerosis: 14 year follow up data following first presentation with a clinically isolated syndrome (2002) (1)
Section of biological sciences (1984) (1)
relapsing-remitting multiple sclerosis minimally disabled patients with early Evidence for grey matter MTR abnormality in (2004) (1)
Rehabilitation of Motor Function (2003) (1)
Clinical trials in neurology: Are rating scales stable across European countries? (2004) (1)
Clinical trials of multiple sclerosis (1997) (1)
Spinal multiple sclerosis: A clinical and MRI study (1995) (1)
Inflammation in early primary progressive multiple sclerosis (2003) (1)
A probabilistic tractography study of the cortico-spinal tract in patients with multiple sclerosis (2007) (1)
A 5 year longitudinal MRI study of ventricular volume in primary progressive multiple sclerosis (2002) (1)
How to measure the effects of rehabilitation (2010) (1)
Magnetisation transfer histogram abnormalities in clinically isolated syndromes suggestive of multiple sclerosis (2005) (1)
Longitudinal Analysis Framework of DWI Data for Reconstructing Structural Brain Networks with Application to Multiple Sclerosis (2018) (1)
MSJ 2018—editorial comment (2018) (1)
Gadolinium enhanced MRI predicts clinical and MRI (2003) (1)
Message from the Editors (2013) (1)
Spinal cord atrophy: A sensitive and reproducible measure of disease progression in multiple sclerosis (MS) (1995) (1)
Quality of life measurement: Is Rasch item analysis too good to be true? (2001) (1)
A 5 year longitudinal MRI study of primary progressive multiple sclerosis (2003) (1)
Editorial 2016 (2016) (1)
Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids (2005) (1)
A longitudinal study of the cortical response to photic stimulation after acute optic neuritis by using functional magnetic resonance imaging: A preliminary analysis (2002) (1)
Rehabilitation solutions in multiple sclerosis (1997) (1)
Promises, promises… (2007) (1)
Disability and T2 MRI abnormalities: A 20 year follow-up of patients with relapse onset of multiple sclerosis (2007) (1)
New MRI techniques and “aggressive” multiple sclerosis (2009) (1)
Spinal cord diffusion imaging and spectroscopy to assess the impact of acute lesions in multiple sclerosis (2007) (1)
Socio-demographic predictors of health-related quality of life in multiple sclerosis and comparisons with other populations (2001) (1)
Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of atrophy (2005) (1)
Acute nephritis—A clinical study (1950) (1)
Diffusion Tensor Imaging of Basal Ganglia in Multiple Sclerosis (2001) (1)
Principles of neurorehabilitation and its application to chronic neurological disorders (2007) (1)
Fourth meeting of the European Neurological Society 25–29 June 1994 Barcelona, Spain (1994) (1)
Adaptive cortical reorganization in acute optic neuritis: Longitudinal functional magnetic resonance imaging study (2004) (1)
Integrated care pathways (ICP) in multiple sclerosis management: An ideal audit tool (1995) (1)
Differences between primary and secondary progressive multiple sclerosis (1999) (1)
Brain Tissue Sodium Concentration in Clinically Isolated Syndrome (S41.007) (2016) (1)
White matter myo-inositol is related to the development of multiple sclerosis within 3 years of presenting with a clinically isolated syndrome (2004) (1)
Coherent waves of myelin plasticity during motor-skill learning (2021) (1)
DUMAS, ZOLA, AND THE LOCKED-IN SYNDROME - REPLY (1985) (1)
Localised damage in normal appearing white matter of early PPMS contributes to disability: a tract-based spatial statistics study (2007) (1)
Motor disability after recovery from transverse myelitis relates to brain functional changes (2004) (0)
The diagnosis of primary progressive multiple sclerosis (1991) (0)
progressive multiple sclerosis . MRI dynamics of brain and spinal cord in and (2003) (0)
IQ . association with brain MRI , dietary state , and Visual evoked potentials in phenylketonuria : (0)
Longitudinal optic radiation changes after acute optic neuritis determined by diffusion tractography (2010) (0)
Multiple Sclerosis: The adult human oligodendrocyte precursor cell: a key player in myelin repair (2010) (0)
Cognitive bias towards pain and MS; mediated by coping styles (2004) (0)
Corpus callosum fractional anisotropy predicts clinical progression and cognitive dysfunction in early primary progressive MS: A 5 year follow-up study. (2010) (0)
2-31-32 Cognitive function in primary progressive multiple sclerosis (MS): A controlled study with MR correlates (1997) (0)
Progressive normal-appearing white matter and grey matter T1 relaxation time abnormalities over 5 years in relapsing-remitting multiple sclerosis (2009) (0)
DRUG THERAPY IN MULTIPLE SCLEROSIS (1999) (0)
Assessing pain in multiple sclerosis; a simple question is not enough (2004) (0)
Cognitive dysfunction in advanced multiple sclerosis (MS) (1995) (0)
Imaging signature of multiple sclerosis phenotypes in grey matter. (2016) (0)
The Cost Of Multiple Sclerosis In 16 European Countries: Functional Status, Symptoms And Mental Factors Drive Costs (2016) (0)
Early corpus callosum damage predicts progression of disability over 3 years in primary progressive multiple sclerosis (2008) (0)
Neurite Orientation Dispersion and Density Imaging (NODDI) at the Onset of Clinically Isolated Syndrome (CIS): New Insights in the Early Microstructural Brain Tissue Changes (P4.157) (2016) (0)
Chapter 5: Basic mechanisms of functional recovery (2010) (0)
Pain and discomfort in multiple sclerosis; equally disruptive but in different areas (2004) (0)
Comprar Multiple Sclerosis | Jürg Kesselring | 9780521888325 | Cambridge University Press (2010) (0)
PPMS T 2 lesions in predicting progression in early Complementary roles of grey matter MTR and and (0)
Variation in Signal Surrounding White Matter Lesions in Primary Progressive Multiple Sclerosis (2009) (0)
Patterns of emotional distress in advanced multiple sclerosis (MS): The relation to impairment and disability (1995) (0)
Predicting personalised risk of disability worsening in multiple sclerosis with machine learning (2022) (0)
Upper cervical cord atrophy reflects disease subtype and disability in patients with multiple sclerosis followed up 20 years from disease onset with a clinically isolated syndrome (2008) (0)
A longitudinal study of spinal cord atrophy in progressive multiple sclerosis (2014) (0)
Spinal cord atrophy as a primary outcome measure in primary progressive multiple sclerosis neuroprotective trials (P6.166) (2015) (0)
MSJ–ETC Editorial (2015) (0)
Reduced Disability Following Rehabilitation in Patients with Progressive Multiple Sclerosis (1995) (0)
Clinical trials in multiple sclerosis - The importance of the outcome measure (2004) (0)
A predictive model to determine the effect of corticosteroids in treating individual patients with multiple sclerosis relapses (2008) (0)
Potential Conflicts of Interest (2010) (0)
The effectiveness of neurological rehabi anon in multiple sclerosis (2006) (0)
The diagnosis and management of multiple sclerosis (2002) (0)
A 1-year serial clinical and MRI study of primary progressive multiple sclerosis (1970) (0)
Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact? (2007) (0)
Gadolinium enhancement of new MRI lesions in progressive multiple sclerosis (1991) (0)
recovery ( fFLAIR ) and spin echo sequences comparison of fast fluid attenuated inversion sclerosis and its correlation with disability : a MRI lesion volume measurement in multiple (1998) (0)
POD04 Analysis of eight rating scales supports the use of functional outcome measures in prion disease clinical trials: experience from the PRION-1 trial and the National Prion Monitoring cohort (2010) (0)
Physical and pharmacological treatments can reduce pain and discomfort without compromising function (2005) (0)
Visual evoked potentials in phenylketonuria: association with brain MRI, dietary state, and intelligence quotient (1995) (0)
Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon (2007) (0)
Visual evoked potentials inphenylketonuria: association withbrain MRI,dietary state,andIQ (1995) (0)
aneurysms and vascular neurosurgeons A failure to communicate : patients with cerebral (2005) (0)
Complementary and Alternative Medicine and Multiple Sclerosis, Second Edition (2007) (0)
0479 Is it rasch to compare thee on another scale? (2005) (0)
Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years (2006) (0)
Factors affecting stiff-legged gait in hereditary and spontaneous spastic paraparesis (2007) (0)
Late diffusion changes in optic radiations predicted by earlier optic nerve structure after optic neuritis, suggesting trans-synaptic effects. (2012) (0)
Cannabinoids in MS - Long-term results from the CAMS (2004) (0)
Neurorehabilitation in multiple sclerosis [Neurorrehabilitaci½n en esclerosis mœltiple] (2005) (0)
Emotion and insight in multiple sclerosis (1997) (0)
Cortical Plasticity after non-arteritict anterior ischaemic optic neuropathy: a longitudinal fMRI study. (2009) (0)
The benefits of exercise in patients with multiple sclerosis (2017) (0)
Hippocampal volume is reduced in relapsing-remitting and primary progressive multiple sclerosis and is associated with memory impairment (2009) (0)
A longitudinal study of spinal cord lesion load in progressive multiple sclerosis (2015) (0)
Perceptions of MRI research in patients with clinically isolated syndromes (2006) (0)
Is GABA abnormal in progressive multiple sclerosis (2014) (0)
A longitudinal evaluation of the disease mechanisms of non-arteritic anterior ischaemic optic neuropathy using functional magnetic resonance imaging (2009) (0)
Chapter 22 Treatment of Progressive Multiple Sclerosis (2003) (0)
Interferon beta-1b in multiple sclerosis - A seminar-in-print - Questions and answers (1996) (0)
SPINAL CORD GLUTAMATE-GLUTAMINE IS ELEVATED IN MS RELAPSE (2014) (0)
A comparison of two neurologic scoring instruments for multiple sclerosis. (1997) (0)
Reply (2010) (0)
Multiple Sclerosis: Preface (2010) (0)
primary progressive multiple sclerosis The effect of interferon beta-1 a on spasticity in (2004) (0)
Neuronal mitochondrial dysfunction contributes to disability in multiple sclerosis: an in-vivo spinal cord imaging study (2009) (0)
Early Neuronal Damage In The Cervical Cord Of Patients With Primary Progressive Multiple Sclerosis Demonstrated By MR Spectroscopy And q-space Imaging (S54.003) (2014) (0)
Can we quantify the benefits of DMDs in multiple sclerosis? (2006) (0)
EEG-EEG connectivity changes after chronic stroke are correlated with functional recovery (2004) (0)
Ron A comparison of neuropsychological deficits in primary and secondary progressive multiple sclerosis (0)
Multiple neurofibromatosis and Robert W. Smith (1984) (0)
Putaminal diffusion tensor imaging measures predict disease severity across human prion diseases (2020) (0)
Prion disease masquerading as Alzheimer's disease (2011) (0)
The aetiology behind AAA disease formation and progression (2009) (0)
4-31-21 Effectiveness of semantic cues in sclerosis (MS): a controlled study of verbal memory encoding and retrieval (1997) (0)
Preparing for therapeutic trials in human prion disease: clinical and laboratory approaches to improve early diagnosis and monitoring of disease progression (2014) (0)
Neutralising Antibodies to Interferon Β Authors' Reply (0)
Recovery from optic neuritis is associated with a reorganization of the cerebral response to visual stimulation: A functional magnetic resonance imaging study (1999) (0)
Spinal cord atrophy separates early relapsing-remitting and primary progressive multiple sclerosis: a multimodal MRI study (2006) (0)
0513 Developing rating scales for neurological diseases: Lessons from rasch analysis (2005) (0)
Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis (2008) (0)
Does white matter damage predict later grey matter changes in early primary-progressive MS? (2012) (0)
Brain metabolite changes in the early clinical stages of primary progressive multiple sclerosis (2004) (0)
Relating functional reorganisation in multiple sclerosis to clinical measures in a multi-centre study (2006) (0)
Increased total sodium concentration in asymptomatic T2 lesions in clinically isolated syndrome (2016) (0)
Emergence of thalamic MTR abnormality in minimally disabled early relapsing-remitting MS patients (2004) (0)
Comparing the 2005 and 2001 McDonald criteria for the diagnosis of multiple sclerosis in clinically isolated syndrome patients (2006) (0)
Gadolinium enhancing lesions decrease over time in early primary progressive multiple sclerosis (2008) (0)
Longitudinal changes in structural cortical networks in early PPMS (2016) (0)
Multiple sclerosis: Plate section (2010) (0)
Volumetric Examination of MS Plaques and Correlation with EDSS Ratings (2009) (0)
Early pericalcarine atrophy in acute optic neuritis is associated with conversion to MS (2011) (0)
P14 Quantification of glutamate in the cortex, hippocampus and thalamus and its relationship with cognitive performance in multiple sclerosis (2012) (0)
Different TRADD expression discriminates between multiple sclerosis disease subtypes (2006) (0)
Magnims: EC network for developing optimal MR techniques to monitor treatments for preventing disability in multiple sclerosis (1995) (0)
Serial MR spectroscopy of the white matter in the first 3 years after the onset of a clinically isolated syndrome suggestive of multiple sclerosis (2006) (0)
Radiological-only conversion to multiple sclerosis following a clinically isolated syndrome (2009) (0)
Disability after 20 years in a multiple sclerosis cohort followed from onset with a clinically isolated syndrome (2006) (0)
Grey matter microstructural and volumetric short-term changes in early relapsing and progressive MS (2012) (0)
Anterograde trans-synaptic degeneration after optic neuritis: earlier optic nerve atrophy predicts later optic radiation damage (2015) (0)
Deep grey matter atrophy in patients with clinically isolated syndromes suggestive of multiple sclerosis (2005) (0)
Reduced tissue integrity in the splenium of the corpus callosum predicts progression of disability over five years in early primary progressive multiple sclerosis (2009) (0)
Cortical motor reorganisation in primary progressive multiple sclerosis (2004) (0)
Abnormalities in normal looking brain tissue are present in early primary progressive multiple sclerosis and correlate with disability: A magnetisation transfer imaging study (2004) (0)
Clinical governance implications of using mitoxantrone within neurology - lessons from a specialist centre (2004) (0)
Methodology for the estimation of the extension of a white matter tract into and through associated grey matter. (2010) (0)
022 Voxelwise analysis of cerebral diffusion tensor imaging in prion diseases (2012) (0)
The relationship between the T2-MRI abnormalities in CIS patients and the long-term outcome in a 20 year follow-up: a preliminary report (2005) (0)
CognitIve dysfunction after brainstem insult (2008) (0)
Cervical Dystonia Impact Profile (2020) (0)
Spinal cord metabolic changes at onset of a relapse in relapsing remitting multiple sclerosis. (2012) (0)
Measuring clinical change in cervical dystonia: A comparison of the CDIP-58 with existing rating scales (2005) (0)
Frontal lobe disturbances and cognitive functioning in patients with multiple sclerosis (1996) (0)
Multiparametric MRI assessment of brain and cord damage in primary progressive multiple sclerosis: a large-scale, multicentre study (2006) (0)
Gadolinium-enhancement in multiple sclerosis: pathological and clinical significance (1990) (0)
The effect of interferon-beta-1a on magnetisation transfer ratio in primary progressive multiple sclerosis (2004) (0)
Changes in diffusion-based structural brain network in relapsing-remitting multiple sclerosis (2016) (0)
Disability prediction in early PPMS using a magnetic resonance multiparameter approach (2007) (0)
MTR histogram abnormalities in the NAWM and NAGM of patients presenting with clinically isolated syndromes suggestive of multiple sclerosis (2005) (0)
The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale (2004) (0)
Spinal cord atrophy in early primary progressive multiple sclerosis (2004) (0)
Generating synthetic DIR images using multi-parameter maps; application to lesion detection in MS. (2012) (0)
Evidence for progressive normal appearing grey and white matter MTR abnormality in early relapsing-remitting multiple sclerosis: A 2 year follow up study (2003) (0)
Reduced cerebellar grey matter volume is associated with cerebellar dysfunction in multiple sclerosis (2008) (0)
Group connectivity maps of major white-matter pathways in the human brain (2003) (0)
Age-related metabolite changes in healthy spinal cord: A 1H MRS study at 3T. (2013) (0)
LONGITUDINAL-STUDY ON CORRELATIONS BETWEEN DISABILITIES AND CEREBRAL MR CHANGES IN MULTIPLE-SCLEROSIS (1994) (0)
Evaluation of anti-interferon beta neutralising antibodies in subjects with relapsing multiple sclerosis (2007) (0)
Relationship between rehabilitation and functional reorganisation of the memory network in MS (2015) (0)
Changing activity in MS lesions: An MRI study (1989) (0)
Assessing neuronal metabolism in MS by modelling imaging measures. (2010) (0)
Evidence of evolving normal appearing brain tissue diffusion tensor imaging abnormalities in early relapsing-remitting multiple sclerosis (2004) (0)
Neuronal dysfunction in the cerebral cortex of the multiple sclerosis brain demonstrated with quantitative magnetic resonance spectroscopic imaging. (2000) (0)
A novel approach identifies regional changes over time in skeletonised MTR and FA in early primary-progressive MS. (2010) (0)
403 Skull fractures and mild head injury I Moseley 404 A window on the role of dopamine in addiction disorders J L Cummings Review: Neurological aspects of tropical disease (2000) (0)
Spinal cord glutamate-glutamine is elevated at onset of cervical cord relapse in multiple sclerosis (2014) (0)
Longitudinal changes in magnetisation transfer ratio in normal-appearing brain tissues of patients with early primary progressive multiple sclerosis (2005) (0)
Ventricular volume in a cohort of clinically isolated syndrome patients followed up 20 years after the onset of disease (2007) (0)
New insights into repair in MS: A longitudinal spinal cord spectroscopy and atrophy study. (2009) (0)
Diffusion tensor imaging detects corticospinal tract involvement at multiple levels in ALS. (2003) (0)
Brain tissue diffusion abnormalities may occur early in relapsing-remitting multiple sclerosis (2003) (0)
Deep-brain stimulation in Parkinson's disease (2006) (0)
Complementary roles of grey matter MTR and T2 lesion load in determining disability in early primary progressive multiple sclerosis-5-year follow-up study (2009) (0)
Increasing cord atrophy in clinical isolated syndrome group: a 5-year study (2006) (0)
The nature and management of swallowing difficulties in MS (1996) (0)
MRI in phenylketonuria: abnormalities in young adults with late onset neurological disability (1990) (0)
BENIGN MULTIPLE-SCLEROSIS AND SECONDARY PROGRESSIVE MULTIPLE-SCLEROSIS - STUDY USING QUANTITATIVE MAGNETIC-RESONANCE (1993) (0)
The new players in the symptomatic treatment of MS (2012) (0)
Spinal cord diffusion tensor radial diffusivity predicts recovery after a cord relapse in multiple sclerosis (2009) (0)
Is inpatient rehabilitation useful in relapsing-remitting multiple sclerosis? (2003) (0)
Quantification of glutamate in the cortex, hippocampus, and thalamus and its relationship with cognitive performance in MS (2011) (0)
possible mechanism of therapeutic effect . multiple sclerosis : MRI evidence for a High dose steroids in acute relapses of (0)
Joint meeting of the Association of British Neurologists and the Norwegian Neurological Association on the coastal steamer Hurtigruten, 6-9 May 2001 (2001) (0)
Raised white matter myo-inositol after a clinically isolated syndrome is associated with the subsequent development of multiple sclerosis (2006) (0)
Corpus Callosum damage predicts long-term motor progression and cognitive dysfunction in primary progressive multiple sclerosis: a five year TBSS and VBM longitudinal study. (2010) (0)
Treatment of progressive MS – are we any closer? (2015) (0)
Neutralising antibodies to interferon beta are associated with loss of efficacy of treatment and reduced side effects (2007) (0)
Quantification of GABA in the grey matter in multiple sclerosis. (2014) (0)
G349(P) Rare case simulation training enables paediatric trainees to achieve core competencies (2017) (0)
Voxel-based T 2 Relaxometry in Prion Disease (2010) (0)
Predicting disability in patients presenting with optic neuritis: the role of early magnetic resonance imaging parameters (2008) (0)
Duration of enhancement in secondary progessive MS (1990) (0)
Choosing quality of life measures for clinical trials of multiple sclerosis (MS): Evidence-based measurement (2001) (0)
Reproducibility of tracing white-matter pathways in the human brain using DT and Fast Marching Tractography . (2002) (0)
Progressive grey and white matter MTR abnormality in early relapsing-remitting MS (2004) (0)
Grey matter magnetisation transfer changes and atrophy in early primary progressive multiple sclerosis: a voxell-based study (2006) (0)
Functional connectivity changes of the motor network in patients with multiple sclerosis: a multicentre fMRI study (2009) (0)
Application of Lesion Probability Maps to predict progression in primary-progressive multiple sclerosis: a 10-year multi- centre study (2009) (0)
Are GABA levels abnormal in progressive MS (2014) (0)
Structural cortical networks in optic neuritis (early CIS) (2016) (0)
A longitudinal study of T1 relaxation time in normal appearing white matter and grey matter in early primary progressive multiple sclerosis (2006) (0)
The longitudinal relationship between brain lesion loads and atrophy in clinically isolated syndromes and multiple sclerosis. (2002) (0)
Q-space imaging is a marker of repair following spinal cord relapse in MS (2014) (0)
Changes in brain lesion load over 20 years and subsequent brain atrophy in clinically isolated syndrome patients (2008) (0)
British specialist multiple sclerosis centre Interferon beta in multiple sclerosis: experience in a (2008) (0)
Fast simultaneous acquisition of high-resolution brain and cervical spinal cord T1w images to measure spinal cord atrophy: methods and validation. (2010) (0)
Slowing of cerebral atrophy after year 1 in a placebo-controlled trial of interferon beta 1b in secondary progressive multiple sclerosis (2007) (0)
Abnormal connectivity inside the motor network in patients with multiple sclerosis: a multicentre fMRI study (2008) (0)
Longitudinal changes in structural cortical networks after clinically isolated syndrome (2016) (0)
Co-localisation and clinical impact of grey matter lesions and regional grey matter volume loss in multiple sclerosis (2013) (0)
Quadrant specific visual functional MRI in acute optic neuritis (2007) (0)
Relation between serial MRI and the development of disability in patients with clinically isolated syndromes suggestive of multiple sclerosis (2001) (0)
Benign MS:MRI evidence for a less inflammatory disease (1993) (0)
Evidence that normal appearing grey and white matter MTR abnormalities predate symptom onset in relapsing-remitting MS (2004) (0)
A functional magnetic resonance imaging study of the longitudinal response to photic stimulation following acute optic neuritis (2003) (0)
Motor recovery visualised by functional MRI and diffusion tensor imaging (1998) (0)
QUANTITATIVE MRI IN PATIENTS WITH CLINICALLY ISOLATED SYNDROMES SUGGESTIVEOF DEMYELINATION. AUTHORS' REPLY (1999) (0)
Is multiple sclerosis disease activity, as detected by gadolinium-enhanced MRI, associated with virological and immunological evidence of EBV reactivation in the peripheral blood? (2008) (0)
GREY MATTER AND WHITE MATTER VOLUMES AT 20 YEAR FOLLOW-UP OF A MULTIPLE SCLEROSIS AND CLINICALLY ISOLATED SYNDROME COHORT SEEN FROM ONSET (2009) (0)
The relationship between function and structure of the posterior visual pathways following optic neuritis (2004) (0)
Changes in cervical cord MRI metrics in a one-year follow-up study in early primary progressive multiple sclerosis (2015) (0)
T1 and T2 in normal appearing white matter in progressive MS (1990) (0)
A study of the relationship between magnetisation transfer ratio and T1 relaxation time in multiple sclerosis lesions and normal appearing white matter. (2000) (0)
128 Quantification of glutamate in the grey matter and its relationship with cognitive performance in multiple sclerosis (2012) (0)
Urinary neopterin is a sensitive marker of longitudinal interferon beta-1a treatment in primary progressive multiple sclerosis patients (2004) (0)
Glutamate reduces in grey matter of MS patients and correlates with cognitive impairment. (2012) (0)
Optic nerve mean area and magnetization transfer ratio at two years following acute optic neuritis (2004) (0)
Selective morphological changes in the primary visual cortex of CIS patients with optic neuritis (2005) (0)
Proposal for a morphologic classification of atypical idiopathic inflammatory demyelinating lesions of the brain based on conventional magnetic resonance imaging (2006) (0)
Raised urinary neopterin excretion is associated with a better clinical outcome in PP-MS patients treated with interferon beta-1a (2006) (0)
RADIOLOGICAL BUT NOT CLINICAL CONVERSION TO MULTIPLE SCLEROSIS FOLLOWING A CLINICALLY ISOLATED SYNDROME (2009) (0)
Early brain atrophy and lesion load measures relate to clinical status after six years in patients with clinically isolated syndromes (2008) (0)
Repeat brain imaging improves prognostic value of MRI in clinically isolated syndromes suggestive of multiple sclerosis (2000) (0)
Independent component analysis of DTI metrics in multiple sclerosis. (2014) (0)
Medical and surgical treatment of spasticity (1998) (0)
Co-localisation of grey matter volume reduction and grey matter lesions in multiple sclerosis (2012) (0)
A novel, voxel-wise, diffusion tensor analysis of spinal cord in multiple sclerosis. (2010) (0)
Spatial localisation of lesions predicts clinical deterioration in primary progressive multiple sclerosis: a 10-year multi-centre study (2009) (0)
Stratified medicine approach in sporadic Creutzfeldt-Jakob disease greatly increases power in simulated clinical trials (2014) (0)
Longstanding lesions and normal appearing white matter in benign and secondary progressive MS: a quantitative MRI study (1993) (0)
Evaluation of anti-interferon beta antibodies in subjects with multiple sclerosis attending the national hospital for neurology and neurosurgery, London (2007) (0)
The progression of brain atrophy is similar in drug-free MS sub-types: A longitudinal study of a large patient population (2008) (0)
Serial changes in multiple sclerosis studied using dynamic Gd-DTPA enhanced MRI (1989) (0)
Grey matter MTR is related to cognitive impairment in primary progressive multiple sclerosis (2009) (0)
The use of interferon- in the treatment of multiple sclerosis: how big a step in the right direction? (1998) (0)
Disrupted principal network organisation in multiple sclerosis relates to disability (2020) (0)
Dynamic changes in grey matter volume over 5 years in primary progressive multiple sclerosis: a tensor-based morphometry study (2012) (0)
Reduced GABA concentration is associated with physical disability in progressive Multiple Sclerosis (2016) (0)
20.26 Custom made dynamic foot orthoses: Aninvestigation into their effect on balance and gait in people with multiple sclerosis (2005) (0)
Message from the Editors (2012) (0)
Greetings from the Editors (2004) (0)
Differential diagnosis of initial isolated clinical presentations. (2008) (0)
2018 Editors’ commentary (2018) (0)
Message from the Editors (2010) (0)
Therapeutic trial outcome studies. (2012) (0)
MSJ 2020 – Editorial comment (2020) (0)
Editor’s Commentary (2015) (0)
MSJ 2019 - Editorial comment (2019) (0)
Professor lan McDonald (1933—2006) (2007) (0)
Nursing care plans for intrathecal baclofen therapy (2006) (0)
Bright’s Disease (1884) (0)
The management of neurological disease (1994) (0)
Managing spasticity and spasms with exercise (2006) (0)
Further development and validation of the parental illness impact scale (PIIS) (2006) (0)
Recent advances in neurology (1992) (0)
Spasticity clinic integrated care pathway (2006) (0)
Service delivery and models of care (2004) (0)
Refill procedure for Medtronic electronic pumps (2006) (0)
Parental Illness Impact Scale--Revised (2014) (0)
Correction proceedings of the Irish neurological association (1985) (0)
Royal academy of medicine in Ireland section of medicine (1982) (0)
Oligoclonal bands in multiple sclerosis (1985) (0)
Irish neurological association (1986) (0)
Progressive MS seen by MRI (2009) (0)
Arterial compliance in eleven year old children related to foetal doppler measurements. (2000) (0)
Medical procedure for intrathecal baclofen trial injection (2006) (0)
How intrathecal phenol may help you manage your lower-limb spasticity (2006) (0)
Abstracts of the proceedings of the 20th annual meeting of the irish neurological association held on 25th–26th may, 1984 (1985) (0)
How botulinum toxin may help your limb spasticity (2006) (0)
Author response to Dr. Domingue (2018) (0)
Drug treatment of neurological disability (2001) (0)
Irish perinatal society (1993) (0)
Generalised spasticity outcome measures form (2006) (0)
Managing your spasticity and spasms (2006) (0)
Neurologial complications of HIV infection and AIDS (1997) (0)
Addison’s disease in a young girl (1935) (0)
Helper/suppressor ratio in multiple sclerosis. (1984) (0)
Sarcoidosis and the nervous system (1991) (0)
The impact of the disease: a medical view (2004) (0)
[Various diseases accompanied by impotence]. (1951) (0)
Physiotherapy guidelines for intrathecal baclofen therapy (2006) (0)
Late onset neurological deterioration in phenylketonuria clinical and mri findings (1990) (0)
Outcomes in neurological and neurosurgical disorders: Multiple sclerosis (1998) (0)
Specific competencies for intrathecal baclofen specialist nurses (2006) (0)
Irish Society Of Gastroenterology 21st Anniversary Year Meeting, November 1983 (1985) (0)
Recent work on undulant fever and Brucella abortus (1931) (0)
The impact of the disease: a personal view (2004) (0)
Irish Society of Gastroenterology (1984) (0)
How intrathecal baclofen therapy may help to manage your spasticity (2006) (0)
[Hypometabolism in medicine; a critical and pathogenic study]. (1949) (0)
Surgical procedure for intrathecal baclofen pump placement (2006) (0)
Royal academy of medicine in Ireland section of medicine (1985) (0)
Irish neurological association (1984) (0)
Measuring the outcomes in neurorehabilitation (2007) (0)
Structural cortical network reorganization associated with early conversion to multiple sclerosis (2018) (0)

This paper list is powered by the following services:

Other Resources About Alan J Thompson

What Schools Are Affiliated With Alan J Thompson?

Alan J Thompson is affiliated with the following schools: